Lyell Immunopharma

Lyell Immunopharma is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, leveraging novel technology to generate T cells that resist exhaustion and drive durable tumor cytotoxicity.